Clinical Acceleration Capitalizing on Immunovant's ongoing IMVT-1402 data and cash runway to offer end-to-end trial optimization services, including trial design support, adaptive design consultation, biostatistics, patient recruitment networks, and site expansion to speed upcoming readouts.

Strategic Partnerships Pursue licensing and co development discussions around the anti-FcRn portfolio with global pharma and biotech partners, leveraging Immunovant's solid funding profile and runway to de risk deals and align milestones with upcoming readouts.

Data Cloud Analytics Enhance cloud native data infrastructure and analytics services to support biomarker programs, trial optimization, and regulatory submissions, leveraging existing AWS and Microsoft toolchains for integrated data platforms and ML driven insights.

Manufacturing Readiness Support manufacturing and supply chain readiness for potential commercialization, including scale up planning, GMP process development, vendor qualification, and risk management to ensure reliable supply for IMVT assets.

Market Access Develop payer oriented value stories and pricing strategies based on strong early stage autoimmune disease data, crafting HEOR and evidence generation programs to accelerate adoption upon potential approval.